Acquisition by Sam Schlessinger of 189 shares of Assertio Therapeutics subject to Rule 16b-3

ASRT Stock  USD 1.00  0.02  2.04%   
Slightly above 65% of all Assertio Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Assertio Therapeutics stock suggests that some investors are interested at this time. Assertio Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Assertio Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Assertio Therapeutics Officer Svp, General Counsel. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Assertio insider trading alert for acquisition of common stock by Sam Schlessinger, Officer: Svp, General Counsel, on 27th of April 2024. This event was filed by Assertio Therapeutics with SEC on 2024-02-11. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Assertio Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Assertio Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Assertio Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Assertio Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Assertio Therapeutics Fundamental Analysis

We analyze Assertio Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assertio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assertio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Assertio Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Assertio Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Assertio Therapeutics stock to make a market-neutral strategy. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics with similar companies.

Peers

Assertio Therapeutics Related Equities

ESPREsperion Therapeutics   10.24   
0%
100.0%
PCRXPacira BioSciences,   1.62   
0%
15.0%
ALVOAlvotech   0.60   
0%
5.0%
RDYDr Reddys   0.43   
0%
4.0%
CTLTCatalent   0.18   
0%
1.0%
NBIXNeurocrine Biosciences   0.13   
0%
1.0%
AMPHAmphastar   0.04   
1.0%
0%
COLLCollegium Pharmaceutical   0.68   
6.0%
0%
EOLSEvolus   0.80   
7.0%
0%
AMRXAmneal Pharmaceuticals,   0.96   
9.0%
0%
ALKSAlkermes Plc   1.02   
9.0%
0%
ITCIIntracellular   1.09   
10.0%
0%
LFCRLifecore Biomedical   1.20   
11.0%
0%
ANIPANI Pharmaceuticals   3.64   
35.0%
0%
IRWDIronwood Pharmaceuticals   4.09   
39.0%
0%

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.